Barclays Issues Pessimistic Forecast for Exact Sciences (NASDAQ:EXAS) Stock Price
Exact Sciences (NASDAQ:EXAS – Free Report) had its target price decreased by Barclays from $70.00 to $65.00 in a research note issued to investors on Thursday morning,Benzinga reports. Barclays currently has an overweight rating on the medical research company’s stock. Several other research firms also recently commented on EXAS. Robert W. Baird cut their target […]
Exact Sciences (NASDAQ:EXAS – Free Report) had its target price decreased by Barclays from $70.00 to $65.00 in a research note issued to investors on Thursday morning,Benzinga reports. Barclays currently has an overweight rating on the medical research company’s stock. Several other research firms also recently commented on EXAS. Robert W. Baird cut their target […]
